Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Neurology, University of California, Irvine, California, USA.
Cancer Med. 2024 Apr;13(8):e7184. doi: 10.1002/cam4.7184.
Thyroid cancer (TC) is the predominant malignancy within the endocrine system. However, the standard method for TC diagnosis lacks the capability to identify the pathological condition of all thyroid lesions. The metabolomics approach has the potential to manage this problem by identifying differential metabolites.
This study conducted a systematic review and meta-analysis of the NMR-based metabolomics studies in order to identify significant altered metabolites associated with TC.
A systematic search of published literature in any language in three databases including Embase, PubMed, and Scopus was conducted. Out of 353 primary articles, 12 studies met the criteria for inclusion in the systematic review. Among these, five reports belonging to three articles were eligible for meta-analysis. The correlation coefficient of the orthogonal partial least squares discriminant analysis, a popular model in the multivariate statistical analysis of metabolomic data, was chosen for meta-analysis. The altered metabolites were chosen based on the fact that they had been found in at least three studies.
In total, 49 compounds were identified, 40 of which were metabolites. The increased metabolites in thyroid lesions compared normal samples included lactate, taurine, alanine, glutamic acid, glutamine, leucine, lysine, phenylalanine, serine, tyrosine, valine, choline, glycine, and isoleucine. Lipids were the decreased compounds in thyroid lesions. Lactate and alanine were increased in malignant versus benign thyroid lesions, while, myo-inositol, scyllo-inositol, citrate, choline, and phosphocholine were found to be decreased. The meta-analysis yielded significant results for three metabolites of lactate, alanine, and citrate in malignant versus benign specimens.
In this study, we provided a concise summary of 12 included metabolomic studies, making it easier for future researchers to compare their results with the prior findings.
It appears that the field of TC metabolomics will experience notable advancement, leading to the discovery of trustworthy diagnostic and prognostic biomarkers.
甲状腺癌(TC)是内分泌系统中最常见的恶性肿瘤。然而,TC 诊断的标准方法缺乏识别所有甲状腺病变病理状况的能力。代谢组学方法有可能通过识别差异代谢物来解决这个问题。
本研究对基于 NMR 的代谢组学研究进行了系统回顾和荟萃分析,以确定与 TC 相关的显著改变的代谢物。
在 Embase、PubMed 和 Scopus 这三个数据库中以任何语言进行了已发表文献的系统检索。在 353 篇原始文章中,有 12 项研究符合纳入系统评价的标准。其中,有 5 篇报告属于 3 篇文章的内容符合荟萃分析的条件。选择正交偏最小二乘判别分析的相关系数作为代谢组学数据多元统计分析的常用模型进行荟萃分析。选择改变的代谢物是基于它们至少在三项研究中被发现的事实。
总共鉴定出 49 种化合物,其中 40 种为代谢物。与正常样本相比,甲状腺病变中增加的代谢物包括乳酸、牛磺酸、丙氨酸、谷氨酸、谷氨酰胺、亮氨酸、赖氨酸、苯丙氨酸、丝氨酸、酪氨酸、缬氨酸、胆碱、甘氨酸和异亮氨酸。脂质是甲状腺病变中减少的化合物。乳酸和丙氨酸在恶性与良性甲状腺病变中增加,而肌醇、神经鞘氨醇、柠檬酸、胆碱和磷酸胆碱则减少。荟萃分析显示,乳酸、丙氨酸和柠檬酸这三种代谢物在恶性与良性标本之间有显著差异。
在这项研究中,我们对纳入的 12 项代谢组学研究进行了简洁的总结,使得未来的研究人员更容易将他们的结果与之前的发现进行比较。
TC 代谢组学领域似乎将取得显著进展,从而发现可靠的诊断和预后生物标志物。